^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

Anti-tumor activity of motesanib in a medullary thyroid cancer model

Excerpt:
...motesanib inhibited the activity of wild-type Ret (IC(50)=66 nM), while it had limited activity against mutant Ret C634W (IC(50)=1100 nM) or Ret M918T (IC(50)>2500 nM)….motesanib inhibited thyroid tumor xenograft growth predominantly through inhibition of angiogenesis and possibly via a direct inhibition of VEGFR2 and Ret expressed on tumor cells.
DOI:
10.3275/7609